Ophthalmic infections and their anti-infective challenges

Survey of Ophthalmology

Volumn 50, Issue 6 SUPPL. 1, 2005, Pages

  Alfonso, Eduardo ^a   Crider, Julie ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b ALCON RESEARCH LTD   (United States)

Author keywords

Anti infectives; Antibiotic; Moxifloxacin; Penetration; Potency; Safety; Therapy; VIGAMOX

Indexed keywords

CIPROFLOXACIN; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN;

AQUEOUS SOLUTION; CLINICAL TRIAL; CONJUNCTIVITIS; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; ENDOPHTHALMITIS; EYE INFECTION; HUMAN; INCIDENCE; KERATITIS; MEDICAL LITERATURE; MOLECULAR DYNAMICS; NONHUMAN; PH MEASUREMENT; PRIORITY JOURNAL; REVIEW;

EID: 27844546833     PISSN: 00396257     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.survophthal.2005.05.001     Document Type: Article

References (35)

1. R. Abshire, P. Cockrum, J. Crider, and B. Schlech Topical antibacterial therapy for mycobacterial keratitis: potential for surgical prophylaxis and treatment Clin Ther 26 2004 191 196
2. G. Alexandrakis, E.C. Alfonso, and D. Miller Shifting trends in bacterial keratitis in South Florida and emerging resistance to fluoroquinolones Ophthalmology 107 2000 1497 1502
3. E. Aliprandis, J. Ciralsky, and H. Lai Comparative efficacy of topical moxifloxacin versus ciprofloxacin and vancomycin in the treatment of P. aeruginosa and ciprofloxacin-resistant MRSA keratitis in rabbits Cornea 24 2005 201 205
4. D.W. Bratzler, and P.M. Houck Surgical Infection Prevention Guidelines Writers Workgroup: Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project Clin Infect Dis 38 2004 1706 1715
5. N.A. Chaudhry, H.W. Flynn Jr., and T.G. Murray Emerging ciprofloxacin-resistant Pseudomonas aeruginosa Am J Ophthalmol 128 1999 509 510
6. K.M. Colleaux, and W.K. Hamilton Effect of prophylactic antibiotics and incision type on the incidence of endophthalmitis after cataract surgery Can J Ophthalmol 35 2000 373 378
7. Durrie DS, Trattler W: A comparison of therapeutic regimens containing moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% ophthalmic solution for surgical prophylaxis in patients undergoing LASIK or LASEK. J Ocular Pharm Ther 1:236-41, 2005
8. J.G. Ford, A.J.W. Huang, and S.C. Pflugfelder Nontuberculous mycobacterial keratitis in South Florida Ophthalmology 105 1998 1652 1658
9. M.H. Goldstein, R.P. Kowalski, and Y.J. Gordon Emerging fluoroquinolone resistance in bacterial keratitis: five-year review Ophthalmology 106 1999 1313 1318
10. D.P. Han, S.R. Wisniewski, and L.A. Wilson Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study Am J Ophthalmol 122 1996 1 17
11. Hariprasad SM, Blinder KJ, Shah GK,, et al. Penetration pharmacokinetics of topically administered moxifloxacin 0.5% ophthalmic solution in human aqueous and vitreous Arch Ophthalmol 123:39-44, 2005
12. D.C. Hooper Fluoroquinolone resistance among gram-positive cocci Lancet Infect Dis 2 2002 530 538
13. S.C.M. Huang, H.K. Soong, J.-S. Chang, and Y.-S. Liang Non-tuberculous mycobacterial keratitis: a study of 22 cases Br J Ophthalmol 80 1996 962 968
14. J.V. Jester, J.K. Maurer, and W.M. Petroll Application of in vivo confocal microscopy to the understanding of surfactant-induced ocular irritation Toxicol Pathol 24 1996 412 428
15. C.L. Karp, S.S. Tuli, and S.H. Yoo Infectious keratitis after LASIK Ophthalmology 110 2003 503 510
16. Katz HR, Masket S, Lane S,, et al. Absorption of topical moxifloxacin ophthalmic solution into human aqueous humor. Ophthalmology (In press)
17. Kim DH, Stark WJ, O'Brien TP, Dick JD: aqueous penetration and biologoical activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patients. Cornea (In press)
18. T.A. Kovoor, A.S. Kim, and J.P. McCulley Evaluation of the corneal effects of topical ophthalmic fluoroquinolones using in vivo confocal microscopy Eye Contact Lens 30 2004 90 94
19. R.P. Kowalski, D.K. Dhaliwal, and L.M. Karenchak Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates Am J Ophthalmol 136 2003 500 505
20. R.P. Kowalski, E.G. Romanowski, and F.S. Mah Topical prophylaxis with moxifloxacin prevents endophthalmitis in a rabbit model Am J Ophthalmol 138 2004 33 37
21. R. Mather, L.M. Karenchak, E.Q. Romanowski, and R.P. Kowalski Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics Am J Ophthalmol 133 2002 463 466
22. R. Mather, J. Stewart, and T. Prabriputaloong The effect of cataract surgery on ocular levels of topical moxifloxacin Am J Ophthalmol 138 2004 554 559
23. McGee DH, Holt WF, Kastner PR, Rice RL: Safety of moxifloxacin as shown in animal and in vitro studies. Surv Ophthalmol (In press)
24. Y. Nagaki, S. Hayasaka, and C. Kadoi Bacterial endophthalmitis alter small-incision cataract surgery: effect of incision placement and intraocular lens type J Cataract Refract Surg 29 2003 20 26
25. P.E. Newman, R.A. Goodman, and G.O. Waring A cluster of cases of Mycobacterium chelonei keratitis associated with outpatient office procedures Am J Ophthalmol 97 1984 344 348
26. E. Pestova, J.J. Millichap, G.A. Noskin, and L.R. Peterson Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones J Antimicrob Chemother 45 2000 583 590
27. Robertson SM, Curtis MA, Schlech BA,, et al. Ocular pharmacokinetics of moxifloxacin after topical treatment of animals and humans. Surv Ophthalmol 50 (Suppl) 1:S32-S45, 2005
28. Schlech BA, Alfonso E: Overview of the potency of moxifloxacin ophthalmic solution 0.5% (VIGAMOX®). Surv Ophthalmol 50 (Suppl) 1:S7-S15, 2005
29. R. Solomon, E.D. Donnenfeld, and H.D. Perry Penetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor Ophthalmology 112 2005 466 469
30. M. Tanaka, T. Wang, and Y. Onodera Mechanisms of quinolone resistance in Staphylococcus aureus J Infect Chemother 6 2000 131 139
31. B.A. Thibodeaux, J.J. Dajcs, and A.R. Caballero Quantitative comparison of fluoroquinolone therapies of experimental gram-negative bacterial keratitis Curr Eye Res 28 2004 337 342
32. T.L. Thielen, S.S. Castle, and J.E. Terry Anterior ocular infections: an overview of pathophysiology and treatment Ann Pharmacother 34 2000 235 246
33. Wagner RS, Abelson MB, Shapiro A, Torkildsen G: Evaluation of moxifloxacin, ciprofloxacin, gatifloxacin, ofloxacin, and levofloxacin concentrations in human conjunctival tissue. Arch Ophthalmol 123:1282-3, 2005
34. M.G. Wang, J.H. Tran, and G.A. Jacoby Plasmid-mediated quinolone resistance in clinical isolates of Escherichia coli from Shanghai China Antimicrob Agents Chemother 47 2003 2742 2748
35. Yee RW, Setabutr P, Foltermann et al.: The effects of topical moxifloxacin 0.5% ophthalmic solution and galifloxacin 0.3% solution on corneal healing following bilateral photorefractive keratectomy (PRK). Cornea (In press)